???global.info.a_carregar???
Liliana Raimundo obtained the degree in Pathological, Cytological and Thanatological Anatomy (2012) at Instituto Politécnico de Saúde do Norte. In 2014 has completed the MSc degree in Molecular Oncology at Instituto de Ciências Biomédicas de Abel Salazar, University of Porto. During her MSc studies, she was involved in the identification of two small molecule dual inhibitors of the p53-MDM2/MDMX interactions, OXAZ-1 and DIMP53-1. Currently is a PhD student at BiotecHealth in REQUIMTE/LAQV Porto. Published 13 articles in peer-reviewed journals. In their professional activities interacted with 37 collaborator(s) co-authorship of scientific papers. Her PhD thesis, under the supervision of L. Saraiva, mainly focus on the discovery of pharmacological modulators of BRCAs function, seeking for new effective therapies thought inhibition of DNA repair pathways. Additionally, she was involved in the discovery of the first reactivator of the mutant p53R280K (SLMP53-1) and of the first inhibitor of the TAp73 interaction with MDM2 and mutant p53 (LEM2).
Read full resume ↓
Identification

Personal identification

Full name
Liliana Raimundo

Citation names

  • Raimundo, Liliana

Author identifiers

Ciência ID
B21B-623F-AA05
ORCID iD
0000-0001-9003-2601
Scopus Author Id
56401789500

Email addresses

  • liliana-raimundo@live.com (Professional)
  • i13432@ipoporto.min-saude.pt (Professional)

Addresses

  • IPO Porto, 4200-072, Porto, Porto, Portugal (Professional)

Websites

Knowledge fields

  • Medical and Health Sciences
  • Medical and Health Sciences - Basic Medicine - Pharmacology and pharmacy
  • Medical and Health Sciences - Basic Medicine - Pathology
  • Medical and Health Sciences - Clinical Medicine - Oncology
  • Natural sciences - Biological Sciences - Molecular Biology
  • Natural sciences - Biological Sciences - Microbiology
  • Natural sciences - Biological Sciences - Cell Biology

Languages

Language Speaking Reading Writing Listening Peer-review
Portuguese (Mother tongue)
English Proficiency (C2) Proficiency (C2) Proficiency (C2) Proficiency (C2) Proficiency (C2)
Spanish; Castilian Intermediate (B1) Advanced (C1) Elementary (A2) Advanced (C1)
Education
Degree Classification
2016 - 2020
Concluded
 Biotecnologia Molecular e Celular Aplicada às Ciências da Saúde (Doutoramento)
Major in Sem especialidade
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
"Targeting BRCA1 and p53 family of tumor supressors in cancer treatment " (THESIS/DISSERTATION)
2018/10 - 2019/02
Concluded
 Science Communication course (Outros)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
 20
2018/10/12 - 2018/12/21
Concluded
 Blended learning introduction to clinical studies (Outros)
Universidade do Porto Faculdade de Medicina, Portugal
 16
2017/11/11 - 2017/12/12
Concluded
 Time management and personal organization course (Outros)
Universidade do Porto Faculdade de Engenharia, Portugal
 17
2016/09/12 - 2016/09/23
Concluded
 Course in Laboratory animal science, Category C with FELASA Accreditation (Outros)
Universidade do Porto Faculdade de Medicina, Portugal
2016/06/27 - 2016/07/15
Concluded
 Essencial practical course in Molecular and celular Biology (Outros)
Universidade do Porto Faculdade de Medicina, Portugal
 18
2016/04/11 - 2016/04/15
Concluded
 8th Course on Optical Microscopy Imaging for Bioscience (Outros)
Universidade do Porto Instituto de Investigação e Inovação em Saúde, Portugal
2012 - 2014
Concluded
 MSc in Molecular Oncology (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
"Drugging p53 pathway: From yeast to human cells" (THESIS/DISSERTATION)
 18
2008/09 - 2012/07
Concluded
 Pathological, Cytological and Thanatological Anatomy (Licenciatura)
Instituto Politécnico de Saude do Norte Escola Superior de Saúde do Vale do Sousa, Portugal
"Monograph: p53 associada ao prognóstico do Mieloma Múltiplo Monograph: Antropologia Forense – À procura da identidade Project: Estrutura e função normal do osso e cartilagem: Novos Métodos histológicos para demonstração de osso e cartilagem" (THESIS/DISSERTATION)
 14
2012/05/04 - 2012/06/02
Concluded
 Course in Macroscopic description 1ª Edição (Outros)
IPNS Departamento de Ciências e Tecnologias de Diagnóstico, Portugal
Affiliation

Others

Category
Host institution 		Employer
2024/09 - Current Diagnostic and therapeutic thecnitian Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal
2020/09 - 2024/09 Molecular Biology Tecnitian Unilabs Portugal, Portugal
2015/09/10 - 2020/09 PhD student at Biotechealth REQUIMTE LAQV Porto, Portugal
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2019/05/01 - 2019/07/31 Internship at U.O.C. Immunologia e Diagnostica Molecolare Oncologica, coordinated by Dr. Stefano Indraccolo Instituto oncologico Veneto, IRCCS, Italy
2018/01/13 - 2018/04/15 Internship at Laboratory of Tumor Biology coordinated by Dr. Renata Veselska Laboratory of Tumor Biology, Masarykova Univerzita v Brno, Faculty of Sciences, Department of Experimental Biology,, Czech Republic
2014/12/15 - 2015/12/31 Internship at the Drug Discovery & Development research Group coordinated by professor Lucília Saraiva Universidade do Porto Faculdade de Farmácia, Portugal
2013/06/03 - 2014/12/12 MsC curricular internship as Member of the Microbiology/Biotechnology research Group coordinated by prof. Lucília Saraiva REQUIMTE Unidade de Ciências Biomoleculares Aplicadas, Portugal
Universidade do Porto Faculdade de Farmácia, Portugal
(...)
2012/02/01 - 2012/06/29 Internship Centro Hospitalar do Porto, Portugal
Projects

Grant

Designation Funders
2017/04/01 - 2020/05/31 EXPLORING BRCA1 IN CANCER: FROM PREVENTION TO NEW THERAPEUTIC OPPORTUNITIES
SFRH/BD/117949/2016
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
 Fundação para a Ciência e a Tecnologia
Concluded
2016/01/01 - 2016/12/31 BD - EXPLORING BRCA1 IN CANCER: FROM PREVENTION TO NEW THERAPEUTIC OPPORTUNITIES
PD/BI/113926/2015
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
 Fundação para a Ciência e a Tecnologia
Concluded

Contract

Designation Funders
2020/01/01 - 2023/12/31 Applied Molecular Biosciences Unit
UIDP/04378/2020
10.54499/UIDP/04378/2020
UIDB/04378/2020
10.54499/UIDB/04378/2020
Universidade do Porto, Portugal

Universidade Nova de Lisboa, Portugal

Rede de Química e Tecnologia Laboratório Associado para a Química Verde, Portugal

Universidade do Porto Instituto de Ciências Tecnologias e Agroambiente, Portugal

Unidade de Ciências Biomoleculares Aplicadas, Portugal

Universidade Nova de Lisboa Associação para a Inovação e Desenvolvimento da FCT, Portugal
Fundação para a Ciência e a Tecnologia
Concluded
2019/01/01 - 2019/12/31 Unidade de Ciências Biomoleculares Aplicadas
UID/Multi/04378/2019
Rede de Química e Tecnologia Laboratório Associado para a Química Verde, Portugal

Unidade de Ciências Biomoleculares Aplicadas, Portugal

Universidade Nova de Lisboa Associação para a Inovação e Desenvolvimento da FCT, Portugal

Universidade do Porto Instituto de Ciências Tecnologias e Agroambiente, Portugal

Universidade do Porto Faculdade de Ciências, Portugal
Fundação para a Ciência e a Tecnologia
Concluded
2016/06/01 - 2019/06/01 Navigating through marine-derived fungi: bioprospection and synthesis of bioactive secondary metabolites and analogues as chemotherapic agents
PTDC/MAR-BIO/4694/2014
PTDC/MARBIO/4694/2014
Cooperativa de Ensino Superior Politécnico e Universitário, Portugal
 Fundação para a Ciência e a Tecnologia
Concluded
2016/04/01 - 2019/04/01 Targeting p53 family proteins: on the route to new anticancer agents
PTDC/DTP-FTO/1981/2014
Universidade do Minho, Portugal

Universidade de Coimbra, Portugal

Associação para a Inovação e Desenvolvimento da FCT, Portugal
Fundação para a Ciência e a Tecnologia
Concluded
Outputs

Publications

Conference paper
  1. Raimundo, Liliana; Sousa, Emilia; Saraiva, Lucília; Gomes, Sara; Soares, Joana; Loureiro, Joana; Leão, Mariana; et al. "Targeting neuroblastoma with a new inhibitor of the TAp73 interaction with MDM2 and mutant p53". 2019.
    10.3390/ecmc2019-06305
  2. Raimundo, Liliana; Saraiva, Lucília; Espadinha, Margarida; Soares, Joana; Loureiro, Joana; Calheiros, Juliana; Nazareth, Nair; et al. "Improving colon cancer therapy with a new promising small-molecule activator of the p53-pathway through disruption of p53-MDM2/MDMX interactions". 2019.
    10.3390/ecmc2019-06306
  3. Santos, Maria; Barcherini, Valentina; Gomes, Sara; Espadinha, Margarida; Soares, Joana; Raimundo, Liliana; Gomes, Célia; et al. "Tryptophanol-derived oxazoloisoindolinones: Novel small molecule p53 activators with promising antitumor activity". 2019.
    10.3390/ecmc2019-06403
Conference poster
  1. Espadinha, Margarida; Valentina Barcherini; Lopes, Elizabeth A.; Raimundo, Liliana; Gomes, Sara; Loureiro, Joana; Reis, Flávio. "New small-molecule dual inhibitors of the p53-MDM2/X interactions to reactivate the p53 pathway". Paper presented in VIII EFMC International Symposium on Advances in Synthetic and Medicinal Chemistry, 2019.
  2. Soares, Joana; Raimundo, Liliana; Pereira, Nuno; Monteiro, Ângelo; Gomes, Ana Sara; Gomes, Sara; Bessa, Cláudia; et al. "Reactivation of mutant p53R280K by SLMP53-1, a potential anticancer drug candidate". Paper presented in XIX National Congress of Biochemistry, 2016.
  3. Soares, Joana; Raimundo, Liliana; Pereira, Nuno; Gomes, Sara; Bessa, Claúdia; Gomes, Ana Sara; Gomes, C.; et al. "Identification of a new reactivator of mutant p53 with in vivo antitumor activity". Paper presented in nternational Conference on Cancer Research and Targeted Therapy, Baltimore, USA, 2016.
  4. Bessa, Cláudia; Soares, Joana; Raimundo, Liliana; Fernandes, Bryan; Gomes, Célia; Reis, Flávio; Soares, Miguel Luz; et al. "Roy-Bz: a new small-molecule selective activator of protein kinase Cd with anticancer activity.". Paper presented in International Conference on Cancer Research and Targeted Therapy, 2016.
  5. Gomes, Ana Sara; Soares, Joana; Raimundo, Liliana; Monteiro, A.; Ramos, Helena; Santos, Maria; Saraiva, Lucília. "Targeting p53:MDM2/MDMX interaction by tryptophanol-derived oxazolopiperidone lactams". Paper presented in Integrative Structural Biology tools for the study of protein-ligand interactions (ISBIO 2015), Lisbon, Portugal, 2015.
  6. Lima, Raquel T.; Pereira, Daniela; Seca, Hugo; Soares, Joana; Gomes, Ana S.; Raimundo, Liliana; Maciel, Cláudia; et al. "Synthesis, screening and evaluation of the activity of new p53 activators in human tumour cell lines". Paper presented in 4th I3S Annual Meeting, Póvoa do Varzim, Portugal, p. 98., 2014.
Journal article
  1. Calheiros, Juliana; Raimundo, Liliana; Morais, João; Matos, Ana Catarina; Minuzzo, Sonia Anna; Indraccolo, Stefano; Sousa, Emília; Silva, Marta Correia da; Saraiva, Lucília. "Antitumor Activity of the Xanthonoside XGAc in Triple-Negative Breast, Ovarian and Pancreatic Cancer by Inhibiting DNA Repair". Cancers 15 24 (2023): 5718. https://doi.org/10.3390/cancers15245718.
    10.3390/cancers15245718
  2. Raimundo, Liliana; Calheiros, Juliana; Saraiva, Lucília. "Exploiting DNA Damage Repair in Precision Cancer Therapy: BRCA1 as a Prime Therapeutic Target". Cancers 13 14 (2021): 3438. https://doi.org/10.3390/cancers13143438.
    10.3390/cancers13143438
  3. Raimundo, Liliana; Paterna, Angela; Calheiros, Juliana; Ribeiro, Joana; Cardoso, David S. P.; Piga, Ilaria; Neto, Susana Junqueira; et al. "BBIT20 inhibits homologous DNA repair with disruption of the BRCA1–BARD1 interaction in breast and ovarian cancer". British Journal of Pharmacology 178 18 (2021): 3627-3647. https://doi.org/10.1111/bph.15506.
    10.1111/bph.15506
  4. Loureiro, Joana B.; Raimundo, Liliana; Calheiros, Juliana; Carvalho, Carla; Barcherini, Valentina; Lima, Nuno R.; Gomes, Célia; et al. "Targeting p53 for Melanoma Treatment: Counteracting Tumour Proliferation, Dissemination and Therapeutic Resistance". Cancers 13 7 (2021): 1648. https://doi.org/10.3390/cancers13071648.
    10.3390/cancers13071648
  5. Ramos, Helena; Soares, Maria I.L.; Silva, Joana; Raimundo, Liliana; Calheiros, Juliana; Gomes, Célia; Reis, Flávio; et al. "A selective p53 activator and anticancer agent to improve colorectal cancer therapy". Cell Reports 35 2 (2021): 108982. https://doi.org/10.1016/j.celrep.2021.108982.
    10.1016/j.celrep.2021.108982
  6. Cerqueira, Fátima; Maia, Marta; Gabriel, Carla; Medeiros, Rui; Cravo, Sara; Ribeiro, Ana Isabel; Dantas, Daniela; et al. "Mechanism of Antifungal Activity by 5-Aminoimidazole-4-Carbohydrazonamide Derivatives against Candida albicans and Candida krusei". Antibiotics 10 2 (2021): 183. https://doi.org/10.3390/antibiotics10020183.
    10.3390/antibiotics10020183
  7. Ramos, Helena; Raimundo, Liliana; Saraiva, Lucília. "p73: From the p53 shadow to a major pharmacological target in anticancer therapy". Pharmacological Research 162 (2020): 105245. https://doi.org/10.1016/j.phrs.2020.105245.
    10.1016/j.phrs.2020.105245
  8. Raimundo, Liliana; Ramos, Helena; Loureiro, Joana B.; Calheiros, Juliana; Saraiva, Lucília. "BRCA1/P53: Two strengths in cancer chemoprevention". Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1873 1 (2020): 188339. http://dx.doi.org/10.1016/j.bbcan.2020.188339.
    Published • 10.1016/j.bbcan.2020.188339
  9. Pereira, Daniela; Lima, Raquel T.; Palmeira, Andreia; Seca, Hugo; Soares, Joana; Gomes, Sara; Raimundo, Liliana; et al. "Design and synthesis of new inhibitors of p53–MDM2 interaction with a chalcone scaffold". Arabian Journal of Chemistry 12 8 (2019): 4150-4161. http://dx.doi.org/10.1016/j.arabjc.2016.04.015.
    10.1016/j.arabjc.2016.04.015
  10. Sousa; Gomes; Raimundo, Liliana; Soares; Loureiro; Leão; Ramos; et al. "Strategies to Discover p53 Activators and a p73 Activator for Neuroblastoma". Proceedings 22 1 (2019): 56. http://dx.doi.org/10.3390/proceedings2019022056.
    10.3390/proceedings2019022056
  11. Gomes, Sara; Raimundo, Liliana; Soares, Joana; Loureiro, Joana B.; Leão, Mariana; Ramos, Helena; Monteiro, Madalena N.; et al. "New inhibitor of the TAp73 interaction with MDM2 and mutant p53 with promising antitumor activity against neuroblastoma". Cancer Letters 446 (2019): 90-102. http://dx.doi.org/10.1016/j.canlet.2019.01.014.
    10.1016/j.canlet.2019.01.014
  12. Gomes, Sara; Bosco, Bartolomeo; Loureiro, Joana B.; Ramos, Helena; Raimundo, Liliana; Soares, Joana; Nazareth, Nair; et al. "SLMP53-2 Restores Wild-Type-Like Function to Mutant p53 through Hsp70: Promising Activity in Hepatocellular Carcinoma". Cancers 11 8 (2019): 1151-1151. http://hdl.handle.net/10316/106844.
    https://doi.org/10.3390/cancers11081151
  13. Raimundo L; Espadinha M; Soares J; Loureiro JB; Alves MG; Santos MMM; Saraiva L. "Improving anticancer activity towards colon cancer cells with a new p53-activating agent.". British journal of pharmacology (2018): http://europepmc.org/abstract/med/30076608.
    10.1111/bph.14468
  14. Facioni, M.S.; Soares, J.; Adinolfi, B.; Gomes, S.; Raimundo, L.; Contini, A.; Ruffoni, B.; et al. "Biological effects of saponin fractions from Astragalus verrucosus in tumor and non-tumor human cells". Natural Product Communications 13 9 (2018): 1105-1110. http://www.scopus.com/inward/record.url?eid=2-s2.0-85053230833&partnerID=MN8TOARS.
  15. Bessa, Cláudia; Soares, Joana; Raimundo, Liliana; Loureiro, Joana B.; Gomes, Célia; Reis, Flávio; Soares, Miguel L.; et al. "Discovery of a small-molecule protein kinase Cd-selective activator with promising application in colon cancer therapy". Cell death & disease (2018): http://hdl.handle.net/10316/107532.
    https://doi.org/10.1038/s41419-017-0154-9
  16. Soares, Joana; Espadinha, Margarida; Raimundo, Liliana; Ramos, Helena; Gomes, Ana Sara; Gomes, Sara; Loureiro, Joana B.; et al. "DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties". Molecular oncology (2017): http://hdl.handle.net/10316/108278.
    https://doi.org/10.1002/1878-0261.12051
  17. Gomes S; Leão M; Raimundo L; Ramos H; Soares J; Saraiva L. "p53 family interactions and yeast: together in anticancer therapy.". Drug discovery today (2016): http://europepmc.org/abstract/med/26891980.
    10.1016/j.drudis.2016.02.007
  18. Soares, Joana; Raimundo, Liliana; Pereira, Nuno A. L.; Monteiro, Ângelo; Gomes, Sara; Bessa, Cláudia; Pereira, Clara; et al. "Reactivation of wild-type and mutant p53 by tryptophanolderived oxazoloisoindolinone SLMP53-1, a novel anticancer small-molecule". Oncotarget (2016): http://hdl.handle.net/10316/108734.
    https://doi.org/10.18632/oncotarget.6775
  19. Leão M; Soares J; Gomes S; Raimundo L; Ramos H; Bessa C; Queiroz G; et al. "Enhanced cytotoxicity of prenylated chalcone against tumour cells via disruption of the p53-MDM2 interaction.". Life sciences (2015): http://europepmc.org/abstract/med/26475964.
    10.1016/j.lfs.2015.10.015
  20. Soares J; Raimundo L; Pereira NA; Dos Santos DJ; Pérez M; Queiroz G; Leão M; Santos MM; Saraiva L. "A tryptophanol-derived oxazolopiperidone lactam is cytotoxic against tumors via inhibition of p53 interaction with murine double minute proteins.". (2015): http://europepmc.org/abstract/med/25814188.
    10.1016/j.phrs.2015.03.006
  21. Leão M; Gomes S; Bessa C; Soares J; Raimundo L; Monti P; Fronza G; Pereira C; Saraiva L. "Studying p53 family proteins in yeast: induction of autophagic cell death and modulation by interactors and small molecules.". (2015): http://europepmc.org/abstract/med/25265062.
    10.1016/j.yexcr.2014.09.028
  22. Soares J; Pereira NA; Monteiro A; Leão M; Bessa C; Dos Santos DJ; Raimundo L; et al. "Oxazoloisoindolinones with in vitro antitumor activity selectively activate a p53-pathway through potential inhibition of the p53-MDM2 interaction.". European Journal of Pharmaceutical Sciences 66 (2014): 138-147. http://europepmc.org/abstract/med/25312347.
    10.1016/j.ejps.2014.10.006
Magazine article
  1. Soares, Joana; Leão, Mariana; Bessa, Cláudia; Gomes, Sara; Maciel, Cláudia; Raimundo, Liliana; Harilal, Nilma; Saraiva, Lucília. "Humanized yeast: in the front line of anticancer drug discovery.", Portuguese Society for Microbiology Magazine, 2012, https://spmicrobiologia.files.wordpress.com/2013/12/2013129-12b.pdf.
Thesis / Dissertation
  1. "Targeting BRCA1 and p53 family of tumor supressors in cancer treatment". PhD, Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, 2020. https://hdl.handle.net/10216/129427.
  2. "Drugging p53 in cancer: from yeast to human cells". Master, Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, 2014. https://repositorio-aberto.up.pt/handle/10216/86675.

Intellectual property

Patent
  1. Raimundo, Liliana. 2017. "Roy-Bz: A small molecule selective activator of protein kinase Cdelta". Portugal.
    Allowed
  2. Bessa, Cláudia; Soares, Joana; Raimundo, Liliana; Gonçalves, Jorge; Simões, Maria de Fátima; Rijo, Patrícia; Saraiva, Lucília. 2017. "A small-molecule selective activator of protein kinase Cdelta.". Portugal.
    Expired
Activities

Oral presentation

Presentation title Event name
Host (Event location)
2020 NEW INHIBITOR OF THE BRCA1-BARD1 INTERACTION WITH ANTICANCER ACTIVITY IN BRCA1-DEFICIENT BREAST AND OVARIAN CANCERS Reunião Anual da Sociedade Portuguesa de Farmacologia, XXXVIII Reunião de Farmacologia Clínica e XIX Reunião de Toxicologia, 5-7 Fevereiro 2020, Coimbra, Portugal.
2019 Improving colon cancer therapy using a novel p53-activating agent XLIX Reunião Anual da Sociedade Portuguesa de Farmacologia, XXXVII Reunião de Farmacologia Clínica, XVIII Reunião de Toxicologia. February 6-8th
Faculdade de Farmácia da Universidade do Porto, Porto, Portugal.
2019 Manio: A new potential anticancer drug candidate by targeting p53 XLIX Reunião Anual da Sociedade Portuguesa de Farmacologia, XXXVII Reunião de Farmacologia Clínica, XVIII Reunião de Toxicologia. February 6-8th
Faculdade de Farmácia da Universidade do Porto, Porto, Portugal.
2019 Targeting Neuroblastoma with a new TAP73 activator. XLIX Reunião Anual da Sociedade Portuguesa de Farmacologia, XXXVII Reunião de Farmacologia Clínica, XVIII Reunião de Toxicologia. February 6-8th
Faculdade de Farmácia da Universidade do Porto, Porto, Portugal.
2018/05/07 Targeting tumor suppressor proteins: discovering new small-molecules with anti-tumor properties 2nd ymposium of the MSc in Oncology IPO Porto
IPO Porto
2017/02/04 Targeting colon cancer with the selective pkc activator Roy-Bz XLVII Reunião anual da sociedade portuguesa de farmacologia, XXXV Reunião de farmacologia clínica, XVI Reunião de toxicologia.
Faculty of pharmacy, University of Coimbra (Coimbra, Portugal)
2016/12/08 Roy-Bz: A small-molecule selective activator of protein kinase C delta with anticancer properties XIX National Congress of Biochemistry
University of Minho (Guimarães, Portugal)
2016/08/10 DIMP53-1: a novel dual inhibitor of the p53 interaction with MDM2 and MDMX IJUP2017 - 10ª Edição do Encontro de Investigação Jovem da Universidade do Porto
University of Porto (Porto, Portugal)
2016/07/09 Identification of a new reactivator of mutant p53 with in vivo antitumor activity 1º encontro annual departamento ciências biológicas
Faculdade De Farmácia Universidade Do Porto (Porto, Portugal)
2016/02/17 Prenylated chalcones with enhanced cytotoxicity against tumor cells through disruption of the p53-MDM2 interaction IJUP - 9ª Edição do Encontro Investigação Jovem da Universidade do Porto
(Porto, Portugal)
2016/02/04 A new dual p53-MDMs interactions inhibitor with promising application in combined therapy XLVI Reunião da Sociedade Portuguesa de Farmacologia, XXXIV Reunião de Farmacologia Clínica, XV Reunião de Toxicologia
(Porto, Portugal)
2016 Enhanced cytotoxicity against human tumour cells using prenylated chalcones through disruption of the p53-MDM2 interaction. ” XXII Encontro Luso-Galego de química. November 9th-11th
Instituto Politécnico de Bragança, Bragança, Portugal
2016 The diterpenoid Roy-Bz: first small molecule selective activator of protein Kinase Cdelta XLVI Reunião Anual da Sociedade Portuguesa de Farmacologia. XXXIV Reunião de Farmacologia clínica. XV Reunião de Toxicologia
Faculdade de Medicina da Universidade do Porto (Porto, Portugal)
2016 The diterpenoid Roy-Bz: first small molecule selective activator of protein Kinase Cdelta XLVI Reunião Anual da Sociedade Portuguesa de Farmacologia. XXXIV Reunião de Farmacologia clínica. XV Reunião de Toxicologia.
Faculdade de Medicina da Universidade do Porto, Porto, Portugal. (Portugal)
2015/12/01 Roy-Bz: the first small molecule selective activator of protein Kinase Cdelta Congresso de Química Orgânica e terapeutica
(Porto, Portugal)
2015/12/01 SLMP53-1: a new reactivator of mutant p53 with potent in vivo antitumor activity Congresso de Química Orgânica e terapêutica
(Porto, Portugal)
2015/07/13 Targeting p53:MDM2/MDMX interaction by tryptophanol-derived oxazolopiperidone lactams ISBIO (integrative structural biology tools for the study of protein-ligand interactions)
Universidade Nova de Lisboa (Porto, Portugal)
2015/07/13 Tryptophanol-derived oxazoloisoindolinone reactivators of mutant p53 ISBIO (integrative structural biology tools for the study of protein-ligand interactions
Universidade Nova de Lisboa (Lisbon, Portugal)
2015/06/10 Novel small molecules with in vitro antitumor activity via inhibition of p53 MDM2 interaction. 6th European Conference EuChem for Life Sciences.
Reitoria Universidade Nova de Lisboa Campolide (Lisbon, Portugal)
2015/05/13 Discovery of a tryptophanol-derived oxazolopiperidone lactam OXAZ-1 with promising antitumor activity via dual inhibition of the p53-MDM2/MDMX interaction IJUP -8th meeting of young researchers
Reitoria da Universidade do Porto (Porto, Portugal)
2015/05/13 LEM2: a new small molecule inhibitor of the p73-MDM2 interaction IJUP-8th meeting of young researchers
Reitoria da Universidade do Porto (Porto, Portugal)
2015/04/29 Humanized yeast in cancer drug discovery: Targeting p53-MDMs interactions 4º Encontro de Biotecnologia Microbiana e Farmacêutica
Faculty of Pharmacy, University of Porto (Porto, Portugal)
2015/02/04 OXAZ-1: A novel small molecule with promising antitumor activity by dual inhibition of the p53-MDM2/MDMX interaction XLV Reunião Anual da Sociedade Portuguesa de Farmacologia
Universidade NOVA de Lisboa (Lisbon, Portugal)
2015/02/04 SLMP531: a new reactivator of mutant p53 with potent antitumor activity XLV Reunião Anual da Sociedade Portuguesa de FarmacologiaNOVA Medical School/Faculty of Medical Sciences
Universidade NOVA de Lisboa (Lisbon, Portugal)
2015/02/04 Novel yeast-based approaches to search for inhibitors of the interaction of p53 family proteins with MDM2/MDMX XLV Reunião Anual da Sociedade Portuguesa de Farmacologia
NOVA Medical School/Faculty of Medical Sciences, Universidade NOVA de Lisboa (Porto, Portugal)
2015/02/04 A new inhibitor of the p53-MDM2 interaction derived from naturally occurring chalcones XLV Reunião Anual da Sociedade Portuguesa de Farmacologia
NOVA Medical School/Faculty of Medical Sciences, Universidade NOVA de Lisboa (Lisbon, Portugal)
2014/02/05 A new small-molecule activator of wild-type and mutant p53 with potential antitumor properties. SPF - Reunião Anual da Sociedade Portuguesa de Farmacologia
(Coimbra, Portugal)
2014 N-tosylindole OXAZ-1: A novel dual inhibitor of the p53- MDM2/MDMX interaction with promising antitumor activity XX Encontro Luso Galego de química. November 26th-28th
Faculty of Pharmacy, University of Porto, Portugal

Event organisation

Event name
Type of event (Role) 		Institution / Organization
2015/04/29 - Current Member of the secretariat of the 4th annual congress Encontro de Biotecnologia Microbiana e Farmacêutica. (2018/07/08 - 2018/07/12) Universidade do Porto Faculdade de Farmácia, Portugal
2014/05/04 - Current Member of the secretariat of the 3rd annual congress Encontro de Biotecnologia Microbiana e Farmacêutica. (2014/05/04)
Congress (Member of the Organising Committee)
 Universidade do Porto Faculdade de Farmácia, Portugal
2017/07/03 - 2017/07/04 Spotting the differences: Biotechnology driving precision medicine (2017)
Congress (Co-organisor)
 Universidade do Porto Faculdade de Farmácia, Portugal

Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal

Universidade do Porto Instituto de Investigação e Inovação em Saúde, Portugal

Course / Discipline taught

Academic session Degree Subject (Type) Institution / Organization
2018/07/08 - 2018/07/12 Organisation of the advanced training course: Model organisms in human disease: the right model for a specific question (Outros) Universidade do Porto Faculdade de Farmácia, Portugal
Distinctions

Award

2021 Programa de apoio à inivação (PAI, PT) - BBIT20: An inhibitor of homologous recombination
2021 BIP proof 2021
Fundação Amadeu Dias, Portugal
2021 BJP ECR award from British Journal of pharmacology
2019 1º ENCONTRO NACIONAL DE JOVENS INVESTIGADORES EM ONCOLOGIA 2019", organized by the Liga Portuguesa Contra o Cancro
Liga Portuguesa Contra o Cancro Núcleo Regional do Norte, Portugal
2018 ACTONp53: p53-activating agents as new anticancer drug candidates